nevirapine has been researched along with Co-infection in 31 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique." | 9.19 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014) |
| "In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs." | 9.17 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. ( Bastos, R; Baudin, E; Bhatt, N; Bonnet, M; Calmy, A; Ciaffi, L; Jani, I; Michon, C; Nunes, E; Rouzioux, C; Silva, C; Sobry, A; Taburet, AM, 2013) |
| "To describe the longitudinal changes in hepatic function among HIV-infected tuberculosis (TB) patients receiving once-daily nevirapine (NVP)- or efavirenz (EFV)-based antiretroviral treatment (ART) along with rifampin-containing anti-TB treatment." | 9.17 | Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. ( Bhavani, PK; Chandrasekar, C; Hannah, E; Kumar, H; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Ramesh, C; Swaminathan, S; Tang, A; Wanke, C, 2013) |
| "Administration of rifampicin along with nevirapine reduces the plasma concentration of nevirapine in human immunodeficiency virus positive individuals with concomitant tuberculosis (HIV-TB patients)." | 9.17 | Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. ( Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S, 2013) |
| " Standard ART includes either nevirapine or efavirenz, however the efficacy of these drugs is limited in patients receiving rifampin treatment for tuberculosis (TB)." | 8.90 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. ( Chen, HJ; Deng, M; Jiang, HY; Ruan, B; Yang, Y; Zhang, MN, 2014) |
| "We investigated the influence of efavirenz (EFV)- or nevirapine (NVP)-based antiretroviral therapy (ART) on lumefantrine plasma exposure in HIV-malaria-coinfected patients and implication of pharmacogenetic variations." | 7.83 | CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2016) |
| "Bedaquiline is a novel drug for the treatment of multidrug-resistant (MDR) TB; combined use with antiretroviral drugs, nevirapine, or ritonavir-boosted lopinavir (LPV/r) is anticipated, but no clinical data from coinfected patients are available." | 6.79 | Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. ( Dooley, KE; Karlsson, MO; Svensson, EM, 2014) |
| "Twenty-two children received antituberculosis and antiretroviral therapy (ART) concurrently for 4 weeks before pharmacokinetic sampling." | 6.77 | Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. ( Burger, DM; Chintu, C; Cook, A; Gibb, DM; McIlleron, H; Merry, C; Mulenga, V; Oudijk, JM; Walker, AS, 2012) |
| "This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique." | 5.19 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014) |
| "In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs." | 5.17 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. ( Bastos, R; Baudin, E; Bhatt, N; Bonnet, M; Calmy, A; Ciaffi, L; Jani, I; Michon, C; Nunes, E; Rouzioux, C; Silva, C; Sobry, A; Taburet, AM, 2013) |
| "To describe the longitudinal changes in hepatic function among HIV-infected tuberculosis (TB) patients receiving once-daily nevirapine (NVP)- or efavirenz (EFV)-based antiretroviral treatment (ART) along with rifampin-containing anti-TB treatment." | 5.17 | Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. ( Bhavani, PK; Chandrasekar, C; Hannah, E; Kumar, H; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Ramesh, C; Swaminathan, S; Tang, A; Wanke, C, 2013) |
| "Administration of rifampicin along with nevirapine reduces the plasma concentration of nevirapine in human immunodeficiency virus positive individuals with concomitant tuberculosis (HIV-TB patients)." | 5.17 | Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. ( Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S, 2013) |
| " Standard ART includes either nevirapine or efavirenz, however the efficacy of these drugs is limited in patients receiving rifampin treatment for tuberculosis (TB)." | 4.90 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. ( Chen, HJ; Deng, M; Jiang, HY; Ruan, B; Yang, Y; Zhang, MN, 2014) |
| "We investigated the influence of efavirenz (EFV)- or nevirapine (NVP)-based antiretroviral therapy (ART) on lumefantrine plasma exposure in HIV-malaria-coinfected patients and implication of pharmacogenetic variations." | 3.83 | CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2016) |
| "Bedaquiline is a novel drug for the treatment of multidrug-resistant (MDR) TB; combined use with antiretroviral drugs, nevirapine, or ritonavir-boosted lopinavir (LPV/r) is anticipated, but no clinical data from coinfected patients are available." | 2.79 | Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. ( Dooley, KE; Karlsson, MO; Svensson, EM, 2014) |
| "Twenty-two children received antituberculosis and antiretroviral therapy (ART) concurrently for 4 weeks before pharmacokinetic sampling." | 2.77 | Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. ( Burger, DM; Chintu, C; Cook, A; Gibb, DM; McIlleron, H; Merry, C; Mulenga, V; Oudijk, JM; Walker, AS, 2012) |
| "Nevirapine exposure was unchanged before and after artemether-lumefantrine administration." | 1.42 | Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. ( Adedeji, WA; Adewole, IF; Akinyinka, OO; Aweeka, FT; Darin, KM; Fehintola, F; Huang, L; Morse, GD; Murphy, RL; Olson, A; Parikh, S; Scarsi, KK; Taiwo, BO, 2015) |
| "Nevirapine (NVP) is an effective nonnucleoside reverse transcriptase inhibitor (NNRTI) of particular interest as it is often used in resource limited countries." | 1.40 | Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine. ( Janphen, K; Kumrapich, B; Praparattanapan, J; Roytrakul, S; Smith, DR; Supparatpinyo, K; Thongtan, T; Wongtrakul, J, 2014) |
| "A retrospective cohort of 124 AIDS patients initiating ART under routine practice conditions was studied." | 1.39 | AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe. ( Borok, MZ; Campbell, TB; Makadzange, AT; Mhlanga, TO; Nelson, BC, 2013) |
| "Demographic, treatment and pregnancy related data were collected." | 1.38 | Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy. ( Boer, K; de Wolf, F; Godfried, MH; Nellen, JF; Smit, C; Snijdewind, IJ; van der Ende, ME, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 29 (93.55) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Hasan, M | 1 |
| Yunihastuti, E | 2 |
| Teguh H, K | 1 |
| Abdullah, M | 1 |
| Bhattacharya, D | 1 |
| Guo, R | 1 |
| Tseng, CH | 1 |
| Emel, L | 1 |
| Sun, R | 1 |
| Chiu, SH | 1 |
| Stranix-Chibanda, L | 1 |
| Chipato, T | 1 |
| Mohtashemi, NZ | 1 |
| Kintu, K | 1 |
| Manji, KP | 1 |
| Moodley, D | 1 |
| Thio, CL | 2 |
| Maldonado, Y | 1 |
| Currier, JS | 1 |
| Su, S | 1 |
| Fairley, CK | 1 |
| Sasadeusz, J | 1 |
| He, J | 1 |
| Wei, X | 1 |
| Zeng, H | 1 |
| Jing, J | 1 |
| Mao, L | 1 |
| Chen, X | 1 |
| Zhang, L | 1 |
| Torimiro, JN | 1 |
| Nanfack, A | 1 |
| Takang, W | 1 |
| Keou, CK | 1 |
| Joyce, AN | 1 |
| Njefi, K | 1 |
| Agyingi, K | 1 |
| Domkam, I | 1 |
| Takou, D | 1 |
| Moudourou, S | 1 |
| Sosso, S | 1 |
| Mbu, RE | 1 |
| O'Donnell, MR | 1 |
| Padayatchi, N | 1 |
| Daftary, A | 1 |
| Orrell, C | 1 |
| Dooley, KE | 2 |
| Rivet Amico, K | 1 |
| Friedland, G | 1 |
| Bonnet, M | 2 |
| Bhatt, N | 1 |
| Baudin, E | 2 |
| Silva, C | 2 |
| Michon, C | 1 |
| Taburet, AM | 2 |
| Ciaffi, L | 1 |
| Sobry, A | 1 |
| Bastos, R | 1 |
| Nunes, E | 1 |
| Rouzioux, C | 1 |
| Jani, I | 1 |
| Calmy, A | 1 |
| Vispo, E | 1 |
| Fernández-Montero, JV | 1 |
| Labarga, P | 1 |
| Barreiro, P | 1 |
| Soriano, V | 1 |
| Chijioke-Nwauche, I | 1 |
| van Wyk, A | 1 |
| Nwauche, C | 1 |
| Beshir, KB | 1 |
| Kaur, H | 1 |
| Sutherland, CJ | 1 |
| Nelson, BC | 1 |
| Borok, MZ | 1 |
| Mhlanga, TO | 1 |
| Makadzange, AT | 1 |
| Campbell, TB | 1 |
| Padmapriyadarsini, C | 1 |
| Bhavani, PK | 1 |
| Tang, A | 1 |
| Kumar, H | 1 |
| Ponnuraja, C | 1 |
| Narendran, G | 1 |
| Hannah, E | 1 |
| Ramesh, C | 1 |
| Chandrasekar, C | 1 |
| Wanke, C | 1 |
| Swaminathan, S | 1 |
| Sinha, S | 1 |
| Raghunandan, P | 1 |
| Chandrashekhar, R | 1 |
| Sharma, SK | 1 |
| Kumar, S | 1 |
| Dhooria, S | 1 |
| Ekka, M | 1 |
| Velpandian, T | 1 |
| Ranjan, S | 1 |
| Ahmad, H | 1 |
| Samantaray, JC | 1 |
| Venkatesh, S | 1 |
| Rewari, BB | 1 |
| Khan, NH | 1 |
| Pandey, RM | 1 |
| Kayentao, K | 1 |
| Guirou, EA | 1 |
| Doumbo, OK | 1 |
| Venkatesan, M | 1 |
| Plowe, CV | 1 |
| Parsons, TL | 1 |
| Hendrix, CW | 1 |
| Nyunt, MM | 1 |
| van Griensven, J | 1 |
| Phirum, L | 1 |
| Choun, K | 1 |
| Thai, S | 1 |
| De Weggheleire, A | 1 |
| Lynen, L | 1 |
| Bhatt, NB | 1 |
| Barau, C | 1 |
| Amin, A | 1 |
| Meggi, B | 1 |
| Furlan, V | 1 |
| Grinsztejn, B | 1 |
| Barrail-Tran, A | 1 |
| Andreotti, M | 1 |
| Pirillo, MF | 1 |
| Liotta, G | 1 |
| Jere, H | 1 |
| Maulidi, M | 1 |
| Sagno, JB | 1 |
| Luhanga, R | 1 |
| Amici, R | 1 |
| Mancini, MG | 1 |
| Gennaro, E | 1 |
| Marazzi, MC | 1 |
| Vella, S | 1 |
| Giuliano, M | 1 |
| Palombi, L | 1 |
| Mancinelli, S | 1 |
| Jiang, HY | 1 |
| Zhang, MN | 1 |
| Chen, HJ | 1 |
| Yang, Y | 1 |
| Deng, M | 1 |
| Ruan, B | 1 |
| Svensson, EM | 1 |
| Karlsson, MO | 1 |
| Wongtrakul, J | 1 |
| Thongtan, T | 1 |
| Roytrakul, S | 1 |
| Kumrapich, B | 1 |
| Janphen, K | 1 |
| Praparattanapan, J | 1 |
| Supparatpinyo, K | 1 |
| Smith, DR | 1 |
| Marszalek, RM | 1 |
| Bae-Harboe, YS | 1 |
| Mahalingam, M | 1 |
| Masterpol, K | 1 |
| Maganda, BA | 1 |
| Minzi, OM | 1 |
| Ngaimisi, E | 1 |
| Kamuhabwa, AA | 1 |
| Aklillu, E | 1 |
| Parikh, S | 2 |
| Fehintola, F | 1 |
| Huang, L | 1 |
| Olson, A | 1 |
| Adedeji, WA | 1 |
| Darin, KM | 1 |
| Morse, GD | 1 |
| Murphy, RL | 1 |
| Taiwo, BO | 1 |
| Akinyinka, OO | 1 |
| Adewole, IF | 1 |
| Aweeka, FT | 1 |
| Scarsi, KK | 1 |
| Nsagha, DS | 1 |
| Pokam, BT | 1 |
| Assob, JC | 1 |
| Njunda, AL | 1 |
| Kibu, OD | 1 |
| Tanue, EA | 1 |
| Ayima, CW | 1 |
| Weledji, PE | 1 |
| Costa, S | 1 |
| Machado, M | 1 |
| Cavadas, C | 1 |
| do Céu Sousa, M | 1 |
| Hobbs, CV | 1 |
| Gabriel, EE | 1 |
| Kamthunzi, P | 1 |
| Tegha, G | 1 |
| Tauzie, J | 1 |
| Petzold, E | 1 |
| Barlow-Mosha, L | 1 |
| Chi, BH | 1 |
| Li, Y | 1 |
| Ilmet, T | 1 |
| Kirmse, B | 1 |
| Neal, J | 1 |
| Deygoo, N | 1 |
| Jean Philippe, P | 1 |
| Mofenson, L | 1 |
| Prescott, W | 1 |
| Chen, J | 1 |
| Musoke, P | 1 |
| Palumbo, P | 1 |
| Duffy, PE | 1 |
| Borkowsky, W | 1 |
| Snijdewind, IJ | 1 |
| Smit, C | 1 |
| Godfried, MH | 1 |
| Nellen, JF | 1 |
| de Wolf, F | 1 |
| Boer, K | 1 |
| van der Ende, ME | 1 |
| Mankhatitham, W | 1 |
| Luaengniyomkul, A | 1 |
| Manosuthi, W | 1 |
| Oudijk, JM | 1 |
| McIlleron, H | 1 |
| Mulenga, V | 1 |
| Chintu, C | 1 |
| Merry, C | 1 |
| Walker, AS | 1 |
| Cook, A | 1 |
| Gibb, DM | 1 |
| Burger, DM | 1 |
| Podzamczer, D | 2 |
| Tiraboschi, JM | 1 |
| Mallolas, J | 1 |
| Curto, J | 1 |
| Cárdenes, MA | 1 |
| Casas, E | 1 |
| Castro, A | 1 |
| Echevarría, S | 1 |
| Leal, M | 1 |
| Lopez Bernaldo de Quirós, JC | 1 |
| Moreno, S | 1 |
| Puig, T | 1 |
| Ribera, E | 1 |
| Villalonga, C | 1 |
| Gómez-Sirvent, JL | 1 |
| García-Henarejos, JA | 1 |
| Lopez-Aldeguer, J | 1 |
| Barrufet, P | 1 |
| Force, L | 1 |
| Santos, I | 1 |
| Sanz, J | 1 |
| Nugroho, AW | 1 |
| Wiria, MS | 1 |
| Llibre, JM | 1 |
| Agbaji, O | 1 |
| Meloni, S | 1 |
| Graham, C | 1 |
| Muazu, M | 1 |
| Nimzing, L | 1 |
| Idoko, J | 1 |
| Sankalé, JL | 1 |
| Ekong, E | 1 |
| Murphy, R | 1 |
| Kanki, P | 1 |
| Hawkins, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412] | Phase 3 | 2,026 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa[NCT05633056] | 360 participants (Anticipated) | Interventional | 2023-02-28 | Not yet recruiting | |||
| Randomized Non-inferiority Trial Comparing the Nevirapine-based Antiretroviral Therapy Versus the Standard Efavirenz-based ART for the Treatment of HIV-TB Co-infected Patients on Rifampicin-based Therapy (ANRS 12146 CARINEMO)[NCT00495326] | Phase 2/Phase 3 | 570 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin in Antiretroviral Naive Patients Co-infected With HIV and Tuberculosis in India.[NCT01805258] | Phase 3 | 135 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Phase I, Open-label, Randomized Crossover Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Lopinavir/Ritonavir and Single-dose TMC207 in Healthy Subjects.[NCT00828529] | Phase 1 | 16 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| A Phase I, Open-label, Single-sequence Drug-drug Interaction Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Nevirapine and Single-dose TMC207 in HIV-1 Infected Subjects.[NCT00910806] | Phase 1 | 16 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| P1060 Substudy Comparing Differences in Malaria Parasitemia by Real Time Quantitative PCR in HIV-Infected Infants and Children on PI-Based HAART Versus NNRTI-Based HAART[NCT00719602] | Early Phase 1 | 105 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months
| Intervention | Number of Adverse Events (Number) | ||||
|---|---|---|---|---|---|
| Death | Life-Threatening | Severe | Moderate | Mild | |
| Nevirapine | 26 | 87 | 375 | 694 | 832 |
| Placebo | 30 | 87 | 332 | 677 | 838 |
(NCT00074412)
Timeframe: At Month 6
| Intervention | participants (Number) | |
|---|---|---|
| # of HIV infections at 6 months | # of Infants at risk for HIV infection at 6 months | |
| Nevirapine | 8 | 700 |
| Placebo | 18 | 699 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # Infant Deaths at 18 months | # Infants at risk of death at 18 months | |
| Nevirapine | 26 | 678 |
| Placebo | 30 | 684 |
(NCT00074412)
Timeframe: At Months 6 and 18
| Intervention | participants (Number) | |
|---|---|---|
| Number of Infants Alive and HIV-free at 6 months | Number of Infants Alive and HIV-free at 18 months | |
| Nevirapine | 689 | 629 |
| Placebo | 683 | 616 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # of infants with HIV infection at 18 months | # of infants @ risk for HIV infection at 18 months | |
| Nevirapine | 16 | 664 |
| Placebo | 23 | 663 |
1 review available for nevirapine and Co-infection
| Article | Year |
|---|---|
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines | 2014 |
9 trials available for nevirapine and Co-infection
| Article | Year |
|---|---|
Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV.
Topics: Anti-HIV Agents; Birth Weight; Coinfection; Double-Blind Method; Female; Hepatitis B; Hepatitis B vi | 2021 |
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzo | 2013 |
Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymp | 2013 |
Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropa | 2013 |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Half-Life; | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060.
Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Coinfection; Drug Therapy, Combination | 2016 |
Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Cholesterol, HDL; Coinfection; Cyclopropanes; Female; HIV | 2012 |
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
Topics: Anti-HIV Agents; Antibiotics, Antitubercular; Case-Control Studies; Child, Preschool; Coinfection; F | 2012 |
21 other studies available for nevirapine and Co-infection
| Article | Year |
|---|---|
Incidence and predictors of nevirapine and efavirenz-associated rash among Indonesian HIV patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Exanthema; | 2022 |
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induce | 2018 |
Rates of HBV, HCV, HDV and HIV type 1 among pregnant women and HIV type 1 drug resistance-associated mutations in breastfeeding women on antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Cameroon; Coinfection; Drug Resistance, Viral; F | 2018 |
Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Substitution; Fem | 2019 |
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug | 2013 |
HIV-positive nigerian adults harbor significantly higher serum lumefantrine levels than HIV-negative individuals seven days after treatment for Plasmodium falciparum infection.
Topics: Adult; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Artemether, Lumefantri | 2013 |
AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Coinfection; Drug Therapy, Combination; | 2013 |
Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection.
Topics: Adult; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Coinfection; Drug Inte | 2014 |
Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Coinfection; C | 2014 |
The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; Hepatitis B; He | 2014 |
Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.
Topics: Alanine Transaminase; Anti-HIV Agents; Biomarkers; Blood Proteins; Chemical and Drug Induced Liver I | 2014 |
Painless penile papule.
Topics: Adenine; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biops | 2015 |
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; ATP Binding Cassette Transporter, | 2016 |
Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; Case-Control Studies; Coinfection; | 2015 |
HAART, DOTS and renal disease of patients co-infected with HIV/AIDS and TB in the South West Region of Cameroon.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiretroviral Therapy, Highly Active; Cameroon; Co | 2015 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Co | 2016 |
Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cohort Studies; Coinfection; Drug Th | 2012 |
Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Cohort Studi | 2012 |
Influence of rifampicin on nevirapine plasma concentration in HIV-TB coinfected patients.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Coinfection; Cross-Sectional Studies; Female; H | 2012 |
Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Dose-Respo | 2012 |
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induce | 2013 |